Gain Therapeutics (GANX) Operating Expenses (2020 - 2026)

Gain Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $4.7 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 8.01% year-over-year to $4.7 million in Q2 2026; TTM through Jun 2026 was $19.3 million, a 11.82% increase from a year earlier, with the FY2025 full-year figure at $18.7 million, down 8.06% from the prior year.
• Operating Expenses was $4.7 million for Q2 2026 at Gain Therapeutics, down from $5.4 million in the prior quarter.
• The five-year high for Operating Expenses was $8.2 million in Q2 2024, with the low at $3.3 million in Q4 2024.
• Average Operating Expenses over 5 years is $5.0 million, with a median of $4.7 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses soared 58.54% in 2023, then sank 37.8% in 2025.
• Over 5 years, Operating Expenses stood at $4.6 million in 2022, then slipped by 3.38% to $4.4 million in 2023, then slipped by 24.42% to $3.3 million in 2024, then jumped by 34.07% to $4.5 million in 2025, then rose by 4.83% to $4.7 million in 2026.
• The last three Operating Expenses figures came in at $4.7 million (Q2 2026), $5.4 million (Q1 2026), and $4.5 million (Q4 2025), per Business Quant data.